Fig. 7
Thiram enhanced oHSV efficacy in two immunocompetent allograft mouse models. a Schematic depicting the study design for 4MOSC1 (up panel) and 4T1 (down panel) tumor inoculation and treatment with oHSV and thiram. b Macroscopic appearance of tumors from 4MOSC1 (left panel) and 4T1 (right panel) at the end of the experiment. c Tumor-growth curve of 4MOSC1 (left panel) and 4T1 tumors (right panel). d Proposed mechanism of combining oHSV and m1A inhibition. e, f Representative flow cytometric analysis images (e) and quantification (f) of CD44 and CD62L expression in the CD8+ T cells from TDLNs of 4MOSC1 tumors. g, h Representative flow cytometric analysis images (g) and quantification (h) of CD44 and CD62L expression in the CD4+ T cells from TDLNs of 4MOSC1 tumors. i, j Representative IHC images of CD3 epsilon (i) and PD-L1 (j) of 4MOSC1 tumors. Two-tailed unpaired Student’s t-test (c, f, h). Data were mean with s.e.m (n = 6 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001; ns represents no significance
